Copyright
©The Author(s) 2019.
World J Clin Cases. Aug 6, 2019; 7(15): 1937-1953
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1937
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1937
Clinical trial | Treatment arms (n) | Duration | Primary endpoint | Response ( Primary endpoint) |
Johnston et al[37], 2019 (PALLET) | (A) LET 14 w (103); (B) LET 2 w followed by LET + PAL 12 w (68); (C) PAL 2 w followed by LET + PAL (69); (D) LET + PAL 14 w (67); LET:2.5 mg/d PAL: 125 mg/d | 14 wk | Clinical response by ultrasound and median log-fold change in Ki-67 expression | A vs B + C + D: 54.3% vs 49.5% (P = 0.2), -2.2 vs -4.1(P < 0.001) |
Ma et al[38], 2017 (NeoPalAna) | ANA 1 mg/d (plus goserelin if premenopausal) followed by PAL 125 mg/d on C1D1 (50) | 5 mo | CCCA (Ki67 < 2.7%) on palbociclib plus anastrozole | C1D1 vs C1D15: 26% vs 87% (P < 0.001) |
Arnedos et al[40], 2018 (POP) | (A) PAL 125 mg/d (74); (B) placebo (26) | 14 d | Antiproliferative response, defined as lnKi67 < 1 at day five | 58% vs 12% (P < 0.001) |
Curigliano et al[42], 2016 (MONALEESA-1) | (A) LET 2.5 mg/d (2); (B) LET 2.5 mg/d + RIB 400 mg/d (6); (C) LET 2.5 mg/d + RIB 600 mg/d (3) | 14 d | mean decreases in the Ki67-positive cell fraction from baseline | (A) 69% (range 38%-100%); (B) 96% (range 78%-100%); (C) 92% (range 75%-100%) |
Neo-MONARCH | (A) ANA 2 w; (B) abemaciclib 2 w; (C) ANA + abemaciclib 2 w followed by ANA+ abemaciclib 12 w | 14 wk | Changes in Ki67 expression | Reduced Ki67 in patients 15% vs 59% vs 66% |
Ma et al[46], 2017 | ANA 1 mg/d (plus goserelin if premenopausal) followed by MK-2206 125 mg/w (16) | 4 mo | pCR rate | 0% |
Baselga et al[48], 2009 | (A) LET 2.5 mg/d+ placebo; (B) LET 2.5 mg/d+ everolimus 10 mg/d | 4 mo | OR by clinical palpation | 68.1% vs 59.1% (P = 0.062) |
- Citation: Yao LT, Wang MZ, Wang MS, Yu XT, Guo JY, Sun T, Li XY, Xu YY. Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer. World J Clin Cases 2019; 7(15): 1937-1953
- URL: https://www.wjgnet.com/2307-8960/full/v7/i15/1937.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i15.1937